ATE345790T1 - Kombination von einem aromatasehemmer mit einem bisphosphonat - Google Patents

Kombination von einem aromatasehemmer mit einem bisphosphonat

Info

Publication number
ATE345790T1
ATE345790T1 AT03766348T AT03766348T ATE345790T1 AT E345790 T1 ATE345790 T1 AT E345790T1 AT 03766348 T AT03766348 T AT 03766348T AT 03766348 T AT03766348 T AT 03766348T AT E345790 T1 ATE345790 T1 AT E345790T1
Authority
AT
Austria
Prior art keywords
bisphosphonate
disease
combination
aromatase
aromatase inhibitor
Prior art date
Application number
AT03766348T
Other languages
English (en)
Inventor
Ajay S Bhatnagar
Dean Brent Evans
Juerg Andreas Gasser
Jonathan Green
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0217636A external-priority patent/GB0217636D0/en
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE345790T1 publication Critical patent/ATE345790T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
AT03766348T 2002-07-30 2003-07-29 Kombination von einem aromatasehemmer mit einem bisphosphonat ATE345790T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0217636A GB0217636D0 (en) 2002-07-30 2002-07-30 Organic compounds
US42548202P 2002-11-12 2002-11-12

Publications (1)

Publication Number Publication Date
ATE345790T1 true ATE345790T1 (de) 2006-12-15

Family

ID=31497252

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03766348T ATE345790T1 (de) 2002-07-30 2003-07-29 Kombination von einem aromatasehemmer mit einem bisphosphonat

Country Status (12)

Country Link
US (1) US20060069067A1 (de)
EP (1) EP1534265B1 (de)
JP (1) JP2011057706A (de)
CN (1) CN100593401C (de)
AT (1) ATE345790T1 (de)
AU (1) AU2003250190A1 (de)
BR (1) BR0313081A (de)
CA (1) CA2494345C (de)
DE (1) DE60309887T2 (de)
ES (1) ES2276119T3 (de)
PT (1) PT1534265E (de)
WO (1) WO2004012728A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0328040D0 (en) * 2003-12-03 2004-01-07 Coleman Robert E Pharmaceutical uses of bisphosphonates
WO2005117864A1 (en) * 2004-05-28 2005-12-15 Astrazeneca Ab Combination product comprising anastrozole and a dual prenyl transferase inhibitor
WO2007045027A1 (en) 2005-10-19 2007-04-26 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
CA2965372C (en) 2014-10-22 2023-09-05 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
JP2018534291A (ja) 2015-10-22 2018-11-22 ハバフ セラピューティクス ピーティーワイ エルティーディー マンモグラフィ乳房密度及び／又は乳癌のリスクを低下させる方法
EP3454856B1 (de) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclische degronimere für zielproteinabbau
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
EP3773576A4 (de) 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon-bindemittel zum abbau von ikaros
EP3781156A4 (de) 2018-04-16 2022-05-18 C4 Therapeutics, Inc. Spirocyclische verbindungen
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
AU2020287392A1 (en) 2019-06-03 2021-12-23 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use
WO2023014590A1 (en) * 2021-08-05 2023-02-09 Celanese Eva Performance Polymers Llc Implantable medical device for the delivery of bisphosphonate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
DE3428524A1 (de) * 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4749713A (en) * 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
DE3626058A1 (de) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3776880D1 (de) * 1986-11-21 1992-04-02 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.

Also Published As

Publication number Publication date
CA2494345A1 (en) 2004-02-12
JP2011057706A (ja) 2011-03-24
ES2276119T3 (es) 2007-06-16
WO2004012728A1 (en) 2004-02-12
CN1671371A (zh) 2005-09-21
US20060069067A1 (en) 2006-03-30
DE60309887D1 (de) 2007-01-04
DE60309887T2 (de) 2007-05-16
AU2003250190A1 (en) 2004-02-23
BR0313081A (pt) 2005-07-12
PT1534265E (pt) 2007-02-28
CA2494345C (en) 2011-11-29
EP1534265A1 (de) 2005-06-01
CN100593401C (zh) 2010-03-10
EP1534265B1 (de) 2006-11-22

Similar Documents

Publication Publication Date Title
ATE345790T1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
MX2010006519A (es) Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
BRPI0413255A (pt) uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer
WO2004043374A3 (en) Methods and compositions for treating cancer using proteasome inhibitors
DE60030889D1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
DE60213386D1 (de) Geldanamycinderivate zur krebsbehandlung
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
BRPI0408491A (pt) tratamento da doença de alzheimer
DE60313434D1 (de) Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
BR0314081A (pt) Terapia de combinação compreendendo um bisfosfonato e um inibidor de hmg-coa redutase
EA200501549A1 (ru) Применение экспрессирующего вектора, кодирующего ингибитор il-18, для лечения и/или профилактики заболевания сердца и способ лечения заболевания сердца
PL367707A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
EA200501456A1 (ru) Торий- 227 для применения в радиотерапии заболевания мягких тканей
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer
WO2002074756A3 (de) Urokinase-inhibitoren
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
MXPA01007031A (es) Metodo para tratar enfermedades acrdiacas cronicas.
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
MX2022012252A (es) Metodos para tratar la enfermedad de alzheimer.
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
BRPI0416755A (pt) uso de inibidores de catepsina k para o tratamento de doenças de perda óssea severa
DE60108775T8 (de) Methode zur behandlung von schlaganfall
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1534265

Country of ref document: EP